Jazz Pharmaceuticals and Jeld-Wen faced market challenges and tax inversion merger issues amid an aggressive tariff plan.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jazz Pharmaceuticals and Jeld-Wen faced market challenges and tax inversion merger issues amid an aggressive tariff plan.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jeld-Wen
American company
Nothing else this week.
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
- A tariff plan caused market tanking, impacting companies Cintas and United Rentals.
- Aggressive tariff plan caused market tanking, impacting Cincinnati Financial.
- Donald Trump announced tariffs and the elimination of tax credits.
- Trump, Dimon, and others discussed the threat of massive levies on imported pharmaceuticals while considering financial market trends in Ireland.
Coverage
Newest first; wire copies grouped- StockStory1 Unprofitable Stock to Keep an Eye On and 2 We Turn Down Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to